AbbVie drops lawsuit against EMA after data redaction agreed
This article was originally published in SRA
Executive Summary
AbbVie has withdrawn its lawsuits against the European Medicines Agency after the agency accepted a new set of redacted documents submitted by AbbVie, along with the company's rationale for removing certain commercially confidential information from the clinical study reports that are at the center of the litigation1,2.
You may also be interested in...
Boost For Transparency As EU Court Backs EMA's Approach To Disclosing Clinical Data
The EU General Court has dismissed three cases by pharmaceutical companies that wanted to prevent the European Medicines Agency from disclosing certain data about their marketed medicines on the grounds that it would harm their commercial interests. Firms now have a clearer idea of the standards they will need to meet to claim their information is commercially confidential.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.